including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreWestern licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
Telix Strikes $1.65 Billion Deal for ITM, Bringing Nearly the Entire Radiopharma Chain Under One Company
The Next Generation of NET Theranostics May Target the Same Receptor in a Completely Different Way
Medical Isotopes Still Don’t Have a Real Price Discovery System. That May Have to Change.
The Next Radiopharma Land Grab Is the Last Mile
Curium gets FDA approval for Lu-177 injection for GEP-NETs
